Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - finasteride -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - finasteride -

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - finasteride -

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - finasteride -

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: magnesium stearate; lauroyl macrogolglycerides; lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; sodium starch glycollate type a; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - finasteride mylan is indicated for the treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - finasteride, quantity: 1 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; lauroyl macrogolglycerides; microcrystalline cellulose; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red - finasteride mylan is indicated for the treatment of male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss in men 18 years or older. efficacy has not been demonstrated in men over the age of 41 years. finasteride mylan is not indicated for use in women (see use in pregnancy and clinical studies) or children.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; lauroyl macrogolglycerides; microcrystalline cellulose; pregelatinised maize starch; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - apo-finasteride 5 is indicated for the treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - finasteride, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; lauroyl macrogolglycerides; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red - apo-finasteride 1 is indicated for the treatment of male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss in men 18 years or older. efficacy has not been demonstrated in men over the age of 41 years. apo-finasteride 1 is not indicated for use in women (see use in pregnancy and clinical studies) or children.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - finasteride, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; lauroyl macrogolglycerides; pregelatinised maize starch; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 6000; indigo carmine aluminium lake - pharmacor finasteride 5 is indicated for the treatment of patients with symptomatic benign prostatic hyperplasia (bph) with an enlarged prostate.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - finasteride, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; magnesium stearate; microcrystalline cellulose; pregelatinised maize starch; lauroyl macrogolglycerides; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red - pharmacor finasteride 1 is indicated for the treatment of male pattern hair loss (androgenetic alopecia) to increase hair growth and prevent further hair loss in men 18 years or older. efficacy has not been demonstrated in men over the age of 41 years. pharmacor finasteride 1 is not indicated for use in women (see use in pregnancy and clinical studies) or children.